Neuromodulation market to reach USD 4,342.50Mn by 2030

According to the report published by Allied Market Research, the global neuromodulation market to generate $4,342.50 million by 2030, witnessing a value of $2,480.21 million in 2020, exhibiting a CAGR of 6.2% from 2021 to 2030. This market report provides an in-depth analysis of leading investment pockets, top-performing strategies, market dynamics, market size and forecasts, competitive analysis, and forecast timeframe. It is an essential resource for the emerging market players, and stakeholders to strategically plan and strengthen their competitive edge.

The global neuromodulation market is categorized into various segments based on technology, application, biomaterial, and region. It is offered in both tabular and graphical form, allowing an individual or a commercial organization to benefit perception into the highly profitable and swiftly expanding segments.

By technology, the internal neuromodulation segment held the major share in 2020, contributing to more than four-fifths of the global neuromodulation market, and is expected to maintain its leadership status for the duration of the forecast timeframe. On the other hand, the external neuromodulation segment is expected to witness the highest CAGR of 6.9% from 2021 to 2030.

By biomaterial, the metallic biomaterials segment held the major market share in 2020, holding more than four-fifths of the global neuromodulation market revenue, and is projected to rule the roost by 2030. On the other hand, the ceramic biomaterials segment would display the fastest CAGR of 6.9% from 2021 to 2030.

By region, North America held the major share in 2020, accounting for more than two-fifths of the global neuromodulation market revenue, and is anticipated to retain its dominance during the forecast period. On the other hand, the Asia-Pacific region would cite the fastest CAGR of 7.5% from 2021 to 2030.

The prominent players that have been analyzed and identified in the global neuromodulation market include NeuroPace Inc., Micro Transponder, LivaNova PLC, Bioventus Inc., Abbott, Boston Scientific Corporation, Nevro Corporation, Medtronic, NeuroSigma, and Neuronetics. Allied Market Research